Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al. Leukemia (2008) We read with interest the Phase II study of Moreau et al., 1 evaluating four weekly infusions of single-agent rituximab (375 mg/m 2 ) therapy in a cohort of patients with CD20 þ multiple myeloma (MM) with either stage I, never treated disease, or stage III MM in relapse, or refractory after two lines of therapy. The authors concluded that rituximab as a single agent had minor activity in this cohort of patients with CD20 expression on at least 33% of tumor cells.
Although the authors did not observe a major impact of rituximab therapy in MM, we would like to draw attention to one patient in their study with 100% CD20 expression who experienced an ongoing 18 month minor response, in contrast to the other patients.
There exists a subset of myeloma with a primary IgH translocation involving t(11;14) which is associated more commonly with CD20 expression. Notably, one series demonstrated that 10 out of 12 patients (83%) with CD20 þ MM had t(11;14) in contrast to 5 out of 54 patients with CD20À MM (9%). 2 Clonogenic cells are important in the pathogenesis of MM, and have been described to be CD20 þ . 3 If so, CD20 þ cells represent an attractive target in halting the disease progression. While there have been relatively few reported responses to rituximab in MM, we report notable clinical benefit and improvement in M-spike with rituximab in a patient with newly diagnosed MM who had 90% CD20 þ bone marrow plasma cells (BMPCs) and t(11;14)(q13;q32) by fluorescent in situ hybridization.
Rituximab was used as a single agent in a 67-year-old patient with ISS stage I MM who had presented with exercise intolerance, fatigue and anemia. He had a serum M-spike of 4.5 gm/dl with an IgA level of 4750 gm/dl. The bone marrow revealed 42% plasma cells, 90% of which were strongly CD20 þ (Figure 1 ). Fluorescent in situ hybridization revealed t(11;14) (q13;32) in 60% of BMPCs correlating with the presence of cyclin D1 on immunohistochemical staining (Figure 2) . 4 Five weeks after completion of four weekly cycles of rituximab (375 mg/m 2 ), a decline in serum M-spike and IgA level to a nadir of 3.3 g/dl and 2990 gm/dl, respectively, was noted ( Figure 3) . The therapy was well tolerated except for transient nausea, fever and rigors with the first infusion only. A second course of weekly rituximab Â 4 was initiated, followed by maintenance therapy once every other month. He became asymptomatic and his disease stabilized for 12 months. Subsequent bone marrow studies demonstrated an expanding clone of BMPCs with significantly reduced CD20 expression. Other regimens were therefore offered to him. His MM, however, has progressed through successive therapeutic interventions. As was the case in our patient, stable disease was achieved in all seven of the stage 1 (never treated) patients in the authors' study for 4-15 months. This distinction highlights an important consideration for Histogram of CD20 þ bone marrow plasma cells. Flow cytometry histogram depicts that 90% of CD38 þ bone marrow plasma cells are also CD20 þ .
Letters to the Editor clinicians selecting initial therapy in patients with high CD20 expression.
A targeted approach to eradicating plasma cells with rituximab in our patient with a high proportion of CD20 þ cells and t(11;14) resulted in substantive clinical improvement. It is therefore important to phenotype MM for evidence of potentially targetable antigen expression. 5 The effects of rituximab monotherapy may be short-lived, but this case and the study by Moreau et al. serve as foundations for designing trials with appropriate combination therapies with rituximab or possibly anti-CD20 radioimmunoconjugates, which may have a more robust and durable benefit. 
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